Drug Trial Radar · NCT07747090
A Study of the Efficacy and Safety of FXS6837 Capsules Compared to Eculizumab for 24 Weeks in Patients With PNH.
Last checked: Nov 19, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Dec 10, 2026
Primary completion
May 5, 2028
Study completion Jul 31, 2028
Sponsor
- Lead sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open label study to evaluate the efficacy and safety of FXS6837 capsules compared to eculizumab in naive PNH patients. About 90 PNH patients who are naive to complement inhibitor therapies will be enrolled to take FXS6837 capsules or eculizumab for 24 weeks according to protocol.
Conditions
- Paroxysmal Nocturnal Hemoglobinuria
Interventions
FXS6837 CapsuleDrug
FXS6837 capsule orally taken for 24 weeks
Eculizumab infusionBiological
Eculizumab infusion treated for 24 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with hemoglobin (Hb) level ≥ 120 g/L in at least 3 of 4 measurements between W18 and W24 in the absence of RBC transfusion (defined as no RBC transfusion after W2 through W24)Time frame: 24 weeks from Baseline
Locations
1 site in 1 country. Site status is shown where the registry gives one.
TianJin Medical University General Hospital
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.